Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer

被引：0
|
作者：
O'Rourke, Kate
机构：
来源：
CANCER | 2022年 / 128卷 / 05期
关键词：
D O I：
10.1002/cncr.34102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：938 / 938
页数：1
相关论文
共 50 条
  • [41] A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Planchard, D.
    Li, B. T.
    Murakami, H.
    Shiga, R.
    Lee, C. C.
    Wang, K.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] HER-2 Mutations in Non-Small Cell Lung Cancer
    Sen, Erdem
    Yavas, Guler
    Ata, Ozlem
    MEDICAL JOURNAL OF BAKIRKOY, 2018, 14 (03) : 322 - 325
  • [43] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 42, 10.1200/JCO-24-01883, 2024)
    Goto, Koichi
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    de Langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Kuo, Chih-Hsi
    Yang, James Chih-Hsin
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (30) : 3635 - 3635
  • [44] Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC)
    Liu, Si-Yang
    Jee, Justin
    Santini, Fernando Costa
    Schoenfeld, Adam Jacob
    Eichholz, Jordan
    Johnson, Kaylie
    Martinez, Andres
    Guo, Jiannan
    Riaz, Nadeem
    Lee, Nancy Y.
    Pike, Luke Roy George
    Scher, Howard I.
    Drilon, Alexander E.
    Arcila, Maria E.
    Reis-Filho, Jorge S.
    Razavi, Pedram
    Jones, David Randolph
    Rudin, Charles M.
    Isbell, James M.
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Trastuzumab Deruxtecan Shows Activity in Multiple HER2+ Tumors, Including Gynecologic Cancers
    Coleman
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 364 - 364
  • [46] Targeting HER2 in the treatment of non-small cell lung cancer
    Mar, Nataliya
    Vredenburgh, James J.
    Wasser, Jeffrey S.
    LUNG CANCER, 2015, 87 (03) : 220 - 225
  • [47] Her2-targeted therapies in non-small cell lung cancer
    Swanton, Charles
    Futreal, Andy
    Eisen, Tim
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4377S - 4383S
  • [48] Investigation of HER2 overexpression in non-small cell lung cancer
    Ugocsai, K
    Mándoky, L
    Tiszlavicz, L
    Molnár, J
    ANTICANCER RESEARCH, 2005, 25 (04) : 3061 - 3066
  • [49] HER2-Targeted Therapies in Non-Small Cell Lung Cancer
    Malhotra, Jyoti
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (07) : 334 - 335
  • [50] Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy
    Rivier, Charlene
    Lavaud, Pernelle
    BULLETIN DU CANCER, 2024, 111 (06) : 539 - 540
12345